Evidence map›Paper›PMID 19520899›Full record

ArticleMolecular pharmacology2009

Hepatic CYP3A suppression by high concentrations of proteasomal inhibitors: a consequence of endoplasmic reticulum (ER) stress induction, activation of RNA-dependent protein kinase-like ER-bound eukaryotic initiation factor 2alpha (eIF2alpha)-kinase (PERK) and general control nonderepressible-2 eIF2alpha kinase (GCN2), and global translational shutoff.

Poulomi Acharya, Juan C Engel, Maria Almira Correia

RetractedOpen access · greenAbstract readRetracted Publication
In one paragraph

Article in Molecular pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Impairment of Proteasome Function in Podocytes Leads to CKD.Journal of the American Society of Nephrology : JASN · 2021
    Article
  2. Review
  3. Mitochondria Retrograde Signaling and the UPR mt: Where Are We in Mammals?International journal of molecular sciences · 2015
    Review
  4. Article
  5. Article
  6. The eIF2α kinases: their structures and functions.Cellular and molecular life sciences : CMLS · 2013
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Poulomi AcharyaDept. of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.
Juan C Engel
Maria Almira Correia
University of California, San Francisco · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
HEPATIC DEGRADATION OF P450P ISOZYMESR01GM044037 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CORREIA, MARIA ALMIRA · 1990 to 2023
$8.0M
REGULATION OF HEME METABOLISM IN THE LIVERR01DK026506 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CORREIA, MARIA ALMIRA · 1986 to 2016
$7.1M
Influence of Heme on Hepatic Cytochrome P450 Synthesis and DegradationR56DK026506 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CORREIA, MARIA ALMIRA · 2007 to 2007
$500k
NIDDK NIH HHS DK26506NIDDK NIH HHS P30 DK026743NIDDK NIH HHS P30-DK26743NIDDK NIH HHS R01 DK026506NIGMS NIH HHS GM44037NIGMS NIH HHS R01 GM044037
6 · The paper itself

Abstract

Hepatic cytochromes P450 3A (P450s 3A) are endoplasmic reticulum (ER)-proteins, responsible for xenobiotic metabolism. They are degraded by the ubiquitin-dependent 26S proteasome. Consistent with this, we have shown that proteasomal inhibitors N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132) and N-benzoyloxycarbonyl-Leu-Leu-Leu-B(OH)(2) (MG262) stabilize CYP3A proteins. However, MG132 has been reported to suppress P450s 3A as a result of impaired nuclear factor-kappaB activation and consequently reduced CYP3A protein stability. Because the MG132 concentration used in those studies was 10-fold higher than that required for CYP3A stabilization, we examined the effect of MG132 (0-300 microM) concentration-dependent proteasomal inhibition on CYP3A turnover in cultured primary rat hepatocytes. We found a biphasic MG132 concentration effect on CYP3A turnover: Stabilization at 5 to 10 muM with marked suppression at >100 microM. Proteasomal inhibitors reportedly induce ER stress, heat shock, and apoptotic response. At these high MG132 concentrations, such CYP3A suppression could be due to ER stress induction, so we monitored the activity of PERK [PKR (RNA-dependent protein kinase)-like ER kinase (EIF2AK3)], the ER stress-activated eukaryotic initiation factor 2alpha (eIF2alpha) kinase. Indeed, we found a marked (approximately 4-fold) MG132 concentration-dependent PERK autophosphorylation, along with an 8-fold increase in eIF2alpha-phosphorylation. In parallel, MG132 also activated GCN2 [general control nonderepressible-2 (EIF2AK4)] eIF2alpha kinase in a concentration-dependent manner, but not the heme-regulated inhibitor eIF2alpha kinase [(EIF2AK1)]. Pulse-chase, immunoprecipitation/immunoblotting analyses documented the consequently dramatic translational shutoff of total hepatic protein, including but not limited to CYP3A and tryptophan 2,3-dioxygenase protein syntheses. These findings reveal that at high concentrations, MG132 is indeed cytotoxic and can suppress CYP3A synthesis, a result confirmed by confocal immunofluorescence analyses of MG132-treated hepatocytes.

Indexed as

Cytochrome P-450 CYP3A InhibitorsProteasome InhibitorsAnimalsCells, CulturedCysteine Proteinase InhibitorsCytochrome P-450 CYP3AeIF-2 KinaseEndoplasmic ReticulumEnzyme ActivationHepatocytesHumansLeupeptinsLiverMaleProtein BiosynthesisProtein Serine-Threonine Kinasesbenzyloxycarbonylleucyl-leucyl-leucine aldehydeCysteine Proteinase InhibitorsCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsEIF2AK4 protein, humaneIF-2 KinaseLeupeptinsProteasome InhibitorsProtein Serine-Threonine KinasesRNA

Identifiers

PMID19520899
PMCPMC2730383
OpenAlexW2123149201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.